Details of the Drug
General Information of Drug (ID: DM6RJOI)
| Drug Name |
OXENDLONE
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
oxendolone; 33765-68-3; Prostetin; 16b-Ethyl-19-nortestosterone; UNII-MN4I850D4P; TSAA-291; MN4I850D4P; NCGC00183854-01; Tsaa 291; Oxendolonum [INN-Latin]; Oxendolona [INN-Spanish]; Oxendolone [USAN:INN:JAN]; Oxendolona; Oxendolonum; 16-beta-Ethyl-19-nortestosterone; 16-Ethyl-17-hydroxyester-4-en-3-one; (8R,9S,10R,13S,14S,16S,17S)-16-ethyl-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one; 16beta-Ethyl-17beta-hydroxyestr-4-en-3-one; 16-beta-Ethyl-17-beta-hydroxyestr-4-en-3-one
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 302.5 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 3.4 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


